ProStraken Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Galahiels United Kingdom (1995)
Status: Acquired by Kyowa Hakko Kirin (2011)

Organization Overview

First Clinical Trial
2001
NCT02015260
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Prostrakan Pharmaceuticals | Strakan Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breakthrough Pain (Phase 3)

Condylomata Acuminata (Phase 2)

Fissure in Ano (Phase 3)

Glioma (Phase 2)

Hypogonadism (Phase 3)

Nausea (Phase 4)

Postoperative Nausea and Vomiting (Phase 4)

Vomiting (Phase 4)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 7